PEGS Europe Tablet Banner

Cambridge Healthtech Institute’s 3rd Annual
Display of Antibodies

Empowering Novel Biologics

31 October - 1 November 2016 | EPIC SANA Lisboa Hotel | Lisboa PORTUGAL


Display of antibodies is the engine responsible for the proliferation of novel constructs that are advancing into clinical studies. This meeting will showcase the latest technologies and applications including antibody generation, targeting ion channels and GPCRs, engineering antibodies against immunotherapy targets, phenotypic screening and enhancing developability. Learn how the experts have made significant progress and uncover innovative approaches for improving library design and biophysical properties of biologics, as well as gain insight from a heightened understanding of the immune system.

Preliminary Agenda

PLENARY KEYNOTE PRESENTATIONS

Immunotherapy Approaches in the Clinic

Renier J. Brentjens, M.D., Ph.D., Director, Cellular Therapeutics, Memorial Sloan-Kettering Cancer Center

Biotherapeutic Programs that Re-Direct Cytotoxic Lymphocytes to Cancer Cells

Paul Adam, Ph.D., Executive Director, Immune Modulation and Biotherapeutics Discovery, Boehringer Ingelheim


USING DISPLAY TO ADVANCE IMMUNOTHERAPY

Optimisation of Chimeric Antigen Receptors for T-Cell Cancer Therapy

Martin Pule, Ph.D., Clinical Senior Lecturer, University College London

Combinatorial Display in Development of T-Cell Vaccines

Andrew Sewell, Ph.D., Professor, Division of Infection and Immunity, Cardiff University School of Medicine

How Display and Signaling of CAR Molecules Can Be Used to Redirect the Specificity of Human T Cells

Hinrich Abken, Ph.D., Professor, Genetics & Immunology, Center for Molecular Medicine Cologne, University of Cologne


ANTIBODIES TO GPCRS AND ION CHANNELS

Using Stabilised Receptors as Antigens to Generate Therapeutic Antibodies to GPCRs

Catherine Hutchings, Ph.D., Consultant, Antibody Alliance Management & Strategic Partnering, Heptares Therapeutics Ltd

Pathological Autoantibodies to Ion Channels

Angela C. Vincent, Ph.D., Professor Emeritus, Clinical & Experimental Neuroimmunology, University of Oxford


COMPETITIVE TECHNOLOGIES FOR IMMUNOTHERAPY AGAINST MAJOR AUTOIMMUNE DISEASE

Disease Interception Approaches in Autoimmunity

Louise Jopling, Ph.D., Director, Immunology Scientific Innovation, Johnson & Johnson Innovation Centre

Overview on the Current Antibody Treatment of Multiple Sclerosis

Gavin Giovannoni, MBBCh, Ph.D., FCP (Neurol., SA), FRCP, FRCPath, Professor of Neurology, Centre for Neuroscience and Trauma, Barts and the London School of Medicine and Dentistry

Targeted-Cytokines for the Treatment of Rheumatoid Arthritis

Mattia Matasci, Ph.D., Head, Cell Line Development, Philochem AG

Targeting Therapeutic and Regenerative Biomedicine Specifically to Arthritic Joints

Ahuva Nissim, Ph.D., Reader, Molecular Targeting, Biochemical Pharmacology, William Harvey Research Institute, Queen Mary University of London


ANTIBODY GENERATION

CDR-Restricted Engineering beyond Affinity Maturation

Orla Cunningham, Ph.D., Director GBT, Pfizer

Nanobodies as a Versatile and Clinically Validated Drug Platform

Antonin De Fougerolles, Ph.D., CSO, Ablynx NV

Toward Single Cell Proteome Analysis Using Phage Display of Recombinant Antibodies

Peter Kristensen, Ph.D., Associate Professor, Molecular Engineering, Aarhus University




For more details on the conference, please contact:

Christina Lingham
Executive Director, Conferences
Cambridge Healthtech Institute
Tel: +1 781-972-5464
clingham@healthtech.com

For exhibit & sponsorship opportunities, please contact:

Companies A-K
Jason Gerardi
Business Development Manager
(+1) 781-972-5452
jgerardi@healthtech.com

Companies L-Z
Carol Dinerstein
Director, Business Development
(+1) 781-972-5471
dinerstein@healthtech.com